Pancragen vs Xenin-25
Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride
The Natural Incretin Helper Peptide That Enhances Glucose Control and Insulin Response
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Pancragen
500–500 mcg
Xenin-25
4–4 pmol/kg/min
Frequency
Pancragen
Multiple times daily
Xenin-25
Once daily
Administration
Pancragen
Intramuscular injection
Xenin-25
Intravenous (IV)
Cycle length
Pancragen
8-12 weeks
Xenin-25
Ongoing/indefinite
Onset speed
Pancragen
Gradual (3-4 weeks)
Xenin-25
Moderate (1-2 weeks)
Evidence level
Pancragen
Limited human trials
Xenin-25
Moderate human trials (Phase 1-2)
Benefit ratings
Blood Sugar Balance
Pancreas Protection
Metabolic Aging Support
Glucose Control & Insulin Response
Metabolic Synergy
Natural Physiological Action
Compound specifications
Pancragen
Molecular formula
C26H36N6O9
Molecular weight
576.6 g/mol
Half-life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids
Bioavailability
Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses
CAS number
Not definitively assigned
Xenin-25
Molecular formula
C139H224N38O32S
Molecular weight
2971.6 g/mol
Half-life
10-15 minutes (IV administration, subject to variation)
Bioavailability
IV: ~100%; Subcutaneous: Research-dependent; Oral: Limited due to peptide nature (active research)
CAS number
Not available
Dosing compared
Pancragen
Oral
500 mcg
Twice daily (morning and evening) · 4-week course
Documented oral dose for the Pankragen-Forte capsule: 500 mcg twice daily for 4 weeks in elderly patients with a prediabetic state [3]. The intramuscular route appears only in animal studies with no published human dose, so it is not listed here.
Xenin-25
Intravenous infusion
4 pmol/kg/min (after a brief higher loading ramp of 10.8→7.7→5.6 pmol/kg/min over the first 10 min)
Continuous infusion · Up to ~4 hours (during glucose clamp)
Human IV infusion dose used to amplify GIP-mediated insulin secretion during a hyperglycemic clamp [5]. Research use only.
Best suited for
Pancragen
Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting metabolic aging
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Xenin-25
Supporting healthy glucose metabolism
Xenin-25 is particularly well-suited for individuals focused on supporting healthy glucose metabolism. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing insulin response efficiency
Xenin-25 is particularly well-suited for individuals focused on enhancing insulin response efficiency. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research into metabolic disorder treatment
Xenin-25 is particularly well-suited for individuals focused on research into metabolic disorder treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Pancragen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Mild hypoglycemia
Serious
- No documented serious adverse effects
Xenin-25
Common
- Gastrointestinal Discomfort
- Nausea
- Headache
Uncommon
- Injection Site Reactions
- Mild Fatigue
Serious
- Hypoglycemia Risk
Safety & evidence
Pancragen
Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
- Concurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects
Xenin-25
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Xenin-25 is a 25-amino acid natural gut peptide discovered in 1992 with moderate evidence from Phase 1-2 human clinical trials. The peptide has been extensively studied in metabolic research for over 30 years. Safety profile shows good tolerability in research settings with mild, transient gastrointestinal effects being the most common. Critical limitation: Xenin-25 has NOT completed Phase 3 clinical trials and is not FDA-approved for clinical use. No serious adverse effects have been reported in research studies, but hypoglycemia risk requires careful monitoring when combined with insulin or other glucose-lowering agents. Individual responses to Xenin-25 are generally mild gastrointestinal discomfort, nausea, or headache in the first few days—these typically resolve with continued use. The peptide's glucose-dependent mechanism makes hypoglycemia unlikely when used alone, but additive effects with other agents require medical supervision.
Contraindications
- Pregnancy and breastfeeding
- Severe kidney or liver disease
Which is right for you?
Choose Pancragen if...
- Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
- Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
- Comprehensive Khavinson bioregulator protocols targeting metabolic aging
- Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Choose Xenin-25 if...
- Supporting healthy glucose metabolism
- Enhancing insulin response efficiency
- Research into metabolic disorder treatment